Livingston 2019 / MARQUE / ISRCTN96745365

Study ID(s) and Acronym(s)
MARQUE / ISRCTN96745365 / Managing Agitation and Raising Quality of Life
Current Status of Trial
Completed
Study Aim
Treatment Dementia
Study Design
RCT
Blinding
Double-blind
Intervention type
Non-pharmacological
Intervention
Managing Agitation and Raising Quality of Life (MARQUE) intervention
Dosage and Duration
Randomised care homes (1:1) to the Managing Agitation and Raising Quality of Life (MARQUE) intervention or treatment as usual (TAU)
Absolute Number of Participants
215
Health Status/Diagnosis
Dementia
Primary outcomes
Agitation
Key Points
"Between June 14, 2016, and July 4, 2017, we randomised ten care homes (189 residents) to the MARQUE intervention and ten care homes (215 residents) to TAU. At 8 months, primary outcome data were available for 155 residents in the MARQUE group and 163 residents in the TAU group. At 8 months, no significant differences in mean CMAI scores were identified between the MARQUE and TAU groups (adjusted difference -0.40 [ 95% CI -3.89 to 3.09; p=0.8226]). In the intervention care homes, 84% of all eligible staff completed all sessions. The mean difference in cost between the MARQUE and TAU groups was 204 pound (-215 to 623; p=0.320) and mean difference in quality-adjusted life-years was 0.015 (95% CI -0.004 to 0.034; p=0.127). At 8 months, 27 (14%) of 189 residents in the MARQUE group and 41 (19%) of 215 residents in the TAU group had died. The prescription of antipsychotic drugs was not significantly different between the MARQUE group and the TAU group (odds ratio 0.66; 95% CI 0.26 to 1.69, p=0.3880). Interpretation The MARQUE intervention was not efficacious for agitation although feasible and cost-effective in terms of quality of life. Addressing agitation in care homes might require resourcing for delivery by professional staff of a more intensive intervention, implementing social and activity times, and a longer time to implement change. Funding UK Economic and Social Research Council and the National Institute of Health Research" Livingston 2019